Generation of a human leukocyte antigen-A24-restricted antitumor cell with the use of SART-1 peptide and dendritic cells in patients with malignant brain tumors.
Dendritic cells (DCs) can be the principal initiators of antigen-specific immune responses. In this study, we attempted to generate cytotoxic T-lymphocytes (CTLs) using DCs pulsed with SART-1(254) peptide. Peripheral-blood mononuclear cells (PBMCs) and tumor-infiltrating mononuclear cells (TIMCs) were obtained from 11 patients with brain tumors expressing human leukocyte antigen (HLA)-A24. After stimulation with SART-1(254) peptide, CTLs showing over 15% were observed in one of 4 patients with gliomas and in 4 of 7 patients with metastatic brain tumors. Furthermore, exposure to DCs pulsed with SART-1(254) peptide increased the killing activity of these CTLs by 28.7% and 37.5%, respectively. We conclude that DCs pulsed with SART-1(254) peptide are effective in generating HLA-A24-restricted antitumor cells.
Yoshida
Seiichi
S
Department of Neurosurgery, Niigata Cancer Hospital, Kawagishi-chou, Japan. brain@niigata-cc.niigata.jp
Tanaka
Ryuichi
R
D000951:Antigens, Neoplasm / Q000008:administration & dosage*; D001932:Brain Neoplasms / Q000276:immunology* / Q000556:secondary / Q000628:therapy*; D003601:Cytotoxicity Tests, Immunologic; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology*; D005910:Glioma / Q000276:immunology; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage; D015234:HLA-A Antigens / Q000378:metabolism*; D059871:HLA-A24 Antigen; D006801:Humans; D007167:Immunotherapy; D066298:In Vitro Techniques; D015847:Interleukin-4 / Q000008:administration & dosage; D008175:Lung Neoplasms; D008213:Lymphocyte Activation; D008545:Melanoma / Q000276:immunology / Q000556:secondary / Q000628:therapy; D011994:Recombinant Proteins; D017411:Ribonucleoproteins, Small Nuclear / Q000008:administration & dosage*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage
D000951:Antigens, Neoplasm; D015234:HLA-A Antigens; D059871:HLA-A24 Antigen; D011994:Recombinant Proteins; D017411:Ribonucleoproteins, Small Nuclear; C431323:SART1 protein, human; D014409:Tumor Necrosis Factor-alpha; D015847:Interleukin-4; D016178:Granulocyte-Macrophage Colony-Stimulating Factor